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INTRODUCTION
An aging population from rising life expectancy is now 
common to virtually all developed and most developing 
countries.1 The resulting median age increase poses added 
burden on healthcare systems and further complexity to 
human organ transplantation with increasing numbers 
of older recipients and donors with more comorbidities.2 
The concomitant advances in heart failure management 
together with significantly improved survival have a direct 
impact on transplantation needs and greater demands 
on the continued scarcity of quality donor hearts. These 
factors have led to the introduction of extended criteria 
donor categories including marginal brain dead (MBD) 
and donation after circulatory death (DCD) to meet recip-
ient demand and mitigate against attrition on transplant 
waiting lists.
Based on current standard criteria for brain dead donation 
(DBD), the median donor age is 32 years as reported by the 
International Heart and Lung Transplant Registry3 with an 
upper age limit of 55 years accepted by most transplant cent-
ers. Other key criteria include cardiovascular disease and risk 
factor profile; cardiac function (via transthoracic echocardiog-
raphy) and inotropic requirement; and the exclusion of blood-
borne illnesses and high-risk tumors. Recipient-matched 
Organ Donation and Procurement
Background. Hearts from older donors or procured via donation after circulatory death (DCD) can alleviate transplant 
waitlist; however, these hearts are particularly vulnerable to injury caused by warm ischemic times (WITs) inherent to DCD. This 
study investigates how the combination of increasing donor age and pharmacologic supplementation affects the ischemic tol-
erance and functional recovery of DCD hearts and how age impacts cardiac mitochondrial respiratory capacity and oxidative 
phosphorylation. Methods. Wistar rats (12-, 18-, and 24-mo-old) were subjected to DCD with 20-min fixed WIT. Hearts were 
procured, instrumented onto a Langendorff perfusion circuit, flushed with Celsior preservation solution with or without supple-
mentation (glyceryl trinitrate [GTN]/erythropoietin [EPO]/zoniporide [Z]) and perfused (Krebs-Henseleit buffer, 37°C Langendorff 
30-min, working 30-min). Cardiac functional recovery of aortic flow (AF), coronary flow (CF), cardiac output (CO), and lactate 
dehydrogenase release were measured. Native heart tissue (3-, 12-, and 24-mo) were assessed for mitochondrial respira-
tory capacity. Results. Unsupplemented 18- and 24-month DCD hearts showed a 6-fold decrease in AF recovery relative to 
unsupplemented 12-month DCD hearts. GTN/EPO/Z supplementation significantly increased AF and CO recovery of 18-month 
DCD hearts to levels comparable to supplemented 12-month hearts; however, GTN/EPO/Z did not improve 24-month DCD 
heart recovery. Compared to 12-month heart tissue, 24-month hearts exhibited significantly impaired mitochondrial oxygen flux 
at complex I, II, and uncoupled maximal respiration stage. Conclusions. Reduced ischemic tolerance after DCD was asso-
ciated with increasing age. Pharmacologic supplementation improves functional recovery of rat DCD hearts but only up to age 
18 months, possibly attributed to a decline in mitochondrial respiratory capacity with increasing age.
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criteria include blood group, crossmatch compatibility, gen-
der, and size matching.2,4 In contrast, some transplant centers 
consider MBD donors with an extended upper age limit of 
65 years, high inotropic requirement, cardiac function at the 
lower end of normal range, and prolonged cold ischemic times 
(4–6 h).
One of the challenges when considering DCD donors is 
the ischemic tolerance of the native heart to warm ischemia. 
DCD hearts represent the more extreme spectrum of mar-
ginality, primarily due to the inevitable warm ischemic time 
(WIT) inherent to the DCD donation pathway. At present, a 
functional WIT of <30 min is tolerated with subsequent nor-
mothermic machine perfusion to assess cardiac viability using 
a combination of physiological and biomarker parameters 
(ie, aortic pressure, coronary flow [CF], ECG, lactate concen-
tration in the perfusate), and visual inspection.5 DCD hearts 
can withstand these long WIT and maintain viable functional 
recovery due to supplementation of the cardiac preserva-
tion flush using glyceryl trinitrate (GTN) and erythropoietin 
(EPO)—currently in clinical practice for direct procurement 
DCD protocols within transplantation units in Australia, the 
UK, and Belgium.6-8 Although the DCD donor age is limited to 
55 years,6 it is unclear whether pharmacologic supplementa-
tion can be of benefit for hearts from older DCD donors.
Preclinical rodent and porcine models of DCD heart trans-
plantation have typically utilized young animals.9-11 We have 
previously investigated the effect of pharmacologic condition-
ing with GTN, EPO, and the sodium–hydrogen exchanger 
inhibitor zoniporide (Z) on the cardiac recovery of older DBD 
rodent hearts and observed that supplemented 18-month-old 
DBD hearts exhibited functional recovery to levels observed 
in younger DBD rodent hearts.12 However, the effect of phar-
macologic supplementation on the functional recovery of 
older DCD hearts has not been studied. Here, we investigate 
the effect of aging on the ischemic tolerance of the heart in 
a rodent DCD model and test whether pharmacologic sup-
plementation of the preservation flush with a combination 
of GTN+EPO+Z can enhance functional recovery. Further to 
this, given that these pharmacologic supplements can influ-
ence mitochondrial processes,13,14 we investigate mitochon-
drial function in hearts from older rodents.
MATERIALS AND METHODS
Animals
Male Wistar rats were sourced from Charles River 
Laboratories (Kingston, NY). Animals were aged at the 
Animal Resources Centre (ARC; Canning Vale, Western 
Australia) for 12-, 18-, and 24-month-old studies, trans-
ferred to the BioCORE animal facility (Victor Chang Cardiac 
Research Institute, Darlinghurst, Australia), and allowed to 
acclimatize for at least 7 days before experimental studies. 
Based on studies correlating rat to human age,15 12-, 18-, and 
24-month-old animals were selected to represent human 30-, 
45-, and 60-years of age. An increased incidence of soft tissue 
tumors and skin disease was observed in the 18- and 24-month 
groups (n = 5 and 6, respectively), and when associated with 
irreversible weight loss ≥20%, these animals were culled and 
excluded from the study. A total of 43 animals were used for 
DCD studies; however, 8 animals were excluded (Table 1) due 
to injury of the carotid artery during cannulation or technical 
issues when cannulating onto the ex vivo perfusion circuit. 
Cohorts of 3-month-old animals for mitochondrial studies 
were sourced from the ARC. The study was approved by the 
institutional animal ethics and research committee (Garvan 
Institute, Animal Research Authority #15/32), and all han-
dling and management of the rodents were compliant with 
the Guidelines to Promote the Wellbeing of Animals Used for 
Scientific Purposes (National Health and Medical Research 
Council, Australia) and the Guide for the Care and Use of 
Laboratory Animals (National Institute of Health, Bethesda, 
MD).
Surgical Preparation
Animals were anesthetized with an intraperitoneal injec-
tion of ketamine (80 mg/kg; Cenvet Australia, Kings Park, 
Australia) and 0.15 mL of xylazine (20 mg/mL; Provet, 
Eastern Creek, Australia). Anesthesia was maintained with 
inhaled 1% isoflurane with supplemental oxygen. Pulse oxi-
metry was used to monitor oxygen saturation and heart rate. 
Once sufficiently anesthetized as assessed by the absence of 
withdrawal reflex to a painful stimulus, carotid artery cut-
down was performed, the artery exposed and cannulated with 
a Millar pressure catheter (ADInstruments Inc., Bella Vista, 
Australia) for continuous blood pressure monitoring. The tra-
chea was exposed and encircled using a 2-0 silk tie.
Donation After Circulatory Death Protocol
A clinically relevant DCD protocol was established using a 
rodent model (Figure 1) to closely mimic events during with-
drawal of life support (WLS) in the clinical setting.16 Rodents 
were subjected to DCD via asphyxiation after surgical prepa-
ration under general anesthesia. Once hemodynamics stabi-
lized, a laparotomy was performed, 500 IU of heparin injected 
into the renal vein, and the trachea was ligated marking the 
initiation of WLS. A fixed WIT of 20 min was observed for all 
animals. Upon the completion of the 20-min WIT, a sternot-
omy was performed, the pulmonary veins were ligated, and 
the lungs excised followed by the swift excision of the heart. 
The heart was immersed in ice-cold Celsior preservation solu-
tion (Genzyme, Naarden, the Netherlands) and the aorta and 
pulmonary artery fashioned for instrumentation on an ex-situ 
Langendorff perfusion circuit. The aorta was cannulated and 
the heart flushed with 100 mL of ice-cold Celsior preserva-
tion solution at a flow rate of 20–30 mL/min administered 
via the pressure line. Hearts were flushed with either unsup-
plemented Celsior (C) or supplemented (CS) with 5 U/mL 
recombinant human EPO-alfa (Eprex; Janssen-Cilag, North 
Ryde, Australia), 0.1 mg/mL GTN (Hospira Australia Pty Ltd, 
TABLE 1.
Experimental groups and exclusions for DCD study
Groups Numbers used Exclusions Final numbers used
12C 6 0 6
12CS 8 2 6
18C 6 0 6
18CS 8 2 6
24C 8 3 5
24CS 7 1 6
Total 43 8 35
C, Celsior only group; CS, Celsior supplemented with GTN/EPO/zoniporide; DCD, donation after 
circulatory death; EPO, erythropoietin; GTN, glyceryl trinitrate.
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Mulgrave, Australia), and 1 µmol/L Z (Pfizer Inc, Groton, CT). 
Left atriotomy was performed as a vent to prevent LV disten-
sion and to facilitate cannulation via the left atrial appendage 
for functional assessment during working mode reperfusion. 
In addition to the fixed WIT, 2 other timepoints were consid-
ered: asystolic-to-cardioplegia delivery time (AP) commencing 
after the prescribed stand-off period until the initiation of the 
cold preservation flush; and the cardioplegia-to-reperfusion 
time (CR) from initiation of preservation flush until the com-
mencement of Langendorff perfusion.
After preservation flush, Langendorff reperfusion was 
commenced for a period of 30 min followed by 30 min of 
the working mode using oxygenated Krebs-Henseleit perfu-
sate (composition [mM]: NaCl 118; KCl 4.7; MgSO4 1.2; 
KH2PO4 1.2; NaHCO3 25; CaCl2 1.4; glucose 11; pH 7.3–7.4, 
37°C) under constant preload and after-load conditions. CF 
was measured at regular 5-min intervals including baseline 
during the working mode. Aortic flow (AF), heart rate (HR), 
and mean arterial pressure (MAP) were measured continu-
ously during working mode. The ex-situ circuit and model 
of functional assessment have been previously described.17,18 
The study was terminated if animal death occurred before 
the initiation of DCD withdrawal, there was an injury to 
the left atrial appendage during cannulation, and failure of 
cannulation.
Measurement of Non-Donation After Circulatory 
Death Heart Baseline Hemodynamics
As a comparison group, hearts were excised from 12-, 18-, 
and 24-month-old rats that were not subjected to the DCD 
protocol. Animals were anesthetized as described above, 500 
IU heparin administered via the renal vein, the heart excised 
and immediately immersed in ice-cold preservation solution 
before instrumentation onto the rig, and Langendorff per-
fused for 15 min then working mode for 30 min. Baseline 
hemodynamic measurements of AF, CF, and cardiac output 
(CO) were recorded during working mode reperfusion.
Measurement of Lactate Dehydrogenase Release
Lactate dehydrogenase (LDH) release was measured from 
coronary effluent samples collected during working mode rep-
erfusion using the TOX7 assay kit (Sigma-Aldrich, St. Louis, 
MS) as per the manufacturer’s instruction. LDH efflux was 
normalized to CF [(abs450 nm – abs690 nm/CF × 100)] as previ-
ously described.17
Mitochondrial Functional Assessment of Native 
Heart Tissue
Sections of LV-free wall native tissue from separate 3-, 12-, 
and 24-month-old rat cohorts (not subjected to DCD or perfu-
sion) were collected in BIOPS buffer (composition [mM]: CaK2 
EGTA 2.77; K2EGTA 7.23; Na2ATP 5.77; MgCl2·6H2O 9.56; 
Taurine 20; Na2 phosphocreatine 15; imidazole 20; dithiothrei-
tol 0.5; MES hydrate 50; pH 7.0), and dissected into ~2 – 4 mm 
cardiac fiber bundles. Fiber bundles were incubated for 10 min 
at 4°C in Mitochondrial Respiratory (MiR05) buffer (composi-
tion [mM unless specified otherwise]: EGTA 0.5; MgCl2·6H2O 
3; taurine 20; KH2PO4 10; HEPES 20; D-sucrose 110; BSA 
1 g/L; lactobionic acid 60) containing 280 U/mL catalase. 
After incubation, ~2–3 mg/wet weight individual fiber bundles 
were used for high-resolution respirometry analysis (Oroboros 
Oxygraph2-k, Oroboros Instruments, Austria). The Substrate-
Uncoupler-Inhibitor-Titrations protocol was carried out at 
37°C using the following substrates (µM): malate 2; octanoyl-
carnitine 0.2; adenosine di-phosphate (ADP) 4–20; glutamate 
10; succinate 20; carbonyl cyanide-p-trifluoromethoxyphenyl-
hydrazone (FCCP) 0.5, 1.0, 1.25; rotenone 0.5; and antimycin 
A 2.5. The respiratory states measured were as follows: LN: leak 
respiration in the absence of adenylates, PETF: maximal electron 
flow via electron-transferring flavoprotein after the addition 
of ADP, PCI: submaximal state 3 respiratory capacity specific 
to complex I after the addition of glutamate and pyruvate, 
PMAX: maximal state 3 respiration after second ADP injection, 
ETS: electron transport system capacity after uncoupling with 
FCCP, PCII: submaximal state 3 respiratory capacity specific to 
complex III after addition of rotenone, ROX: residual oxygen 
consumption after addition of antimycin A. Mitochondrial res-
piratory capacity was corrected for wet weight and baseline 
values after permeabilization, and the oxygen flux per volume 
presented as pmol/s/mL/mg wet weight.
Data Analysis
Hemodynamic data were collected and analyzed using 
Labchart (ADInstruments Inc). Statistical analyses of rat 
and heart weights, cardiac hemodynamics, and mitochon-
drial studies were performed using 1-way analysis of vari-
ance (ANOVA) with post hoc Tukey’s multiple comparisons 
test, Dunnett’s multiple comparisons test, or unpaired t test 
where specified (GraphPad Prism v8.0.2, GraphPad Software 
Inc., La Jolla, CA). Statistical analysis of LDH studies was 
performed using repeated-measures 3-way ANOVA for 
serial LDH release combined with factorial ANOVA for age 
and treatment as independent variables using StatView for 
Windows, version 5.0 (SAS Institute Inc, Cary, NC).
RESULTS
Baseline Cohort Characteristics and Cardiac 
Hemodynamics
Compared to 12-month-old rodents, there was a signifi-
cant increase in body weight at 18- and 24 months; however, 
there were no significant differences in heart weight between 
the different age groups (Figure 2A and B). By comparison, 
the weight of 3-month hearts was 2.52 ± 0.12 g (n = 8) and 
FIGURE 1. Rodent DCD protocol. Representative schematic indicating the key steps in the rodent DCD protocol.  DCD, donation after 
circulatory death; MAP, mean arterial pressure.
4 Transplantation DIRECT   ■   2021 www.transplantationdirect.com
significantly lower than all 3 older cohorts (P < 0.05, data not 
shown), indicating that heart weight increased in rats beyond 
3 months. The observed AF recovery of older hearts not sub-
jected to fixed WIT was 36–46 mL/min (Figure  2C). There 
were no significant differences in AF, CF, and CO between 
12-, 18-, and 24-month-old hearts when hemodynamics were 
measured in the absence of warm ischemia and immediately 
after heart procurement (Figure 2C–E).
Key Time Intervals During Withdrawal of Life 
Support
All age groups were subjected to a 20-min fixed WIT based 
on pilot data from our laboratory demonstrating excellent 
recovery with 12 min fixed WIT but no AF recovery when 
WIT was extended to 25 min (data not shown). There were 
no significant differences in the agonal time (time from WLS 
to asystole) between the age groups: 12-month 6.9 ± 1.4 min 
(mean ± SD), 18-month 7.3 ± 1.9 min, and 24-month 7.8 ± 
1.3 min. There were no differences in AP times between the 
age groups: 12-month 6.1 ± 0.9 min, 18-month 6.1 ± 1.4 min, 
and 24-month 5.4 ± 0.9 min. There were also no differences 
in CR times between the age groups: 12-month 7 ± 1.3 min, 
18-month 6.6 ± 1.2 min, and 24-month 6.8 ± 1.2 min.
Functional Recovery of Hearts After Fixed Warm 
Ischemic Time With and Without Pharmacologic 
Supplementation
Hearts from the 12-month-old cohort that were subjected 
to fixed WIT demonstrated an AF recovery of ~13 mL/min; 
however, there was an age-related decline in AF recovery of 
18- and 24-month-old hearts to ~2 mL/min, with a significant 
overall difference in AF with age (P = 0.0411, Figure  3A). 
There were no significant differences in CF recovery between 
the age groups (Figure 3B) but there was a trend for reduced 
CO recovery with increasing age (P = 0.0681, Figure  3C). 
These data indicate that there is an age-related decline in car-
diac functional recovery of DCD hearts.
We next sought to determine whether pharmacologic sup-
plementation of the cardiac preservation solution admin-
istered after the fixed WIT could improve the functional 
recovery of aged DCD hearts. Analysis of AF recovery 
showed that supplementation of 12-month hearts had a 
slight increase in AF recovery; however, in 18-month hearts, 
supplementation resulted in a significant improvement in AF 
recovery (P = 0.0198, Figure 3A). In contrast, the poor AF 
recovery in 24-month-old hearts was not rescued with sup-
plementation (Figure 3A). There were no significant changes 
in CF recovery (Figure 3B). Supplementation had an over-
all significant improvement in CO (P = 0.0341) although 
specifically there was a trend towards significantly improved 
CO recovery within the 18-month group (P = 0.0731, 
Figure 3C). These data indicate that as donor age increases, 
the decline in cardiac functional recovery of DCD hearts can 
potentially be restored with pharmacologic supplementa-
tion; however, the benefits of supplementation are negated 
in 24-month hearts.
Analysis of Lactate Dehydrogenase Efflux as an 
Indicator of Cellular Injury
To determine whether pharmacologic supplementation 
would have an impact on myocardial injury after fixed WIT, 
coronary effluent samples collected during the working mode 
reperfusion were assessed for LDH release. Compared to 
unsupplemented hearts, LDH efflux after 1 min of working 
mode reperfusion showed a trend for reduced LDH efflux in 
12-month and 18-month supplemented hearts but the trend 
for increased LDH efflux in 24-month supplemented hearts 
(Figure 4A); however, these trends did not approach statistical 
significance. Similar trends for reduced LDH efflux in sup-
plemented 12- and 18-month hearts but increased LDH efflux 
in 24-month supplemented hearts were observed after 15 min 
(Figure 4B) and 30 min (Figure 4C) of working mode reperfu-
sion. These data demonstrate that functional improvements 
achieved by supplementation are limited by the age of the 
donor’s heart since hearts beyond 18 months do not respond 
to pharmacologic supplementation.
Mitochondrial Respiratory Capacity in Aged Cardiac 
Tissue
To elucidate whether the age-related decline in cardiac 
functional recovery after DCD could be due to impaired 
mitochondrial function, high-resolution respirometry was 
used to compare the mitochondrial respiratory capacity of 
young 3-month native cardiac tissue with native 12- and 
24-month-old tissue (Figure 5). Overall, cardiac tissue from 
the 12-month group demonstrated oxygen flux profiles sim-
ilar to 3-month tissue at each of the respiratory states meas-
ured. However, compared to both 3- and 12-month native 
heart tissue, tissue from 24-month-old hearts showed a sig-
nificant decline in oxidative phosphorylation at complex 
I, reduced maximal state 3 respiration measured after the 
addition of succinate, reduced ETS capacity measured after 
uncoupling with FCCP, and reduced respiratory capacity of 
complex II after inactivation of complex I with rotenone. 
These data demonstrate that aged cardiac tissue exhib-
its poor mitochondrial respiratory capacity compared to 
younger counterparts.
DISCUSSION
This study shows that DCD hearts exhibit an age-related 
decline in ischemic tolerance and functional recovery which 
can be restored with the use of pharmacologic supplementation 
in rodent donors up to the age of 18 months, the equivalent of 
a 45-year-old human. The use of pharmacologic supplementa-
tion in the cardiac preservation solution improved ischemic 
tolerance and cardiac functional recovery in a rodent DCD 
model for the young and “middle-age” cohort (correspond-
ing to human 30- and 45-y-old) but shows limited effect in 
older cohorts (corresponding to human 60 y old). The pre-
sent study also demonstrated an age-related decline in mito-
chondrial respiration, consistent with the observed decline in 
ischemic tolerance. Our laboratory has previously shown that 
aged DBD rats have increased susceptibility to ischemia-rep-
erfusion injury induced by brain death and prolonged hypo-
thermic storage.12 Our current rodent data support the notion 
that age-related changes in ischemic tolerance influence the 
degree of functional recovery and adds to previous studies 
from our laboratory which demonstrate that pharmacologic 
supplementation can increase the ischemic tolerance in young 
DCD donors and older BD donors.9,12 The current data are 
limited to ischemic tolerance of the donor’s heart and may not 
reflect similar patterns seen in other organ systems. However, 
current clinical data suggest worse survival in recipients of 
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older donor organs (ie, liver, kidneys, pancreas, heart, and 
lung) independent of recipient age group.19
The reduced ischemic tolerance and responsiveness of 
older hearts to pharmacologic supplementation may be due 
to impaired mitochondrial respiratory capacity, as demon-
strated by the reduced oxygen flux profiles of 24-month-old 
hearts compared to 3- and 12-month-old hearts. Given that 
the heart is one of the organs that contain the highest coen-
zyme Q (CoQ) content,20 and CoQ plays a crucial role in elec-
tron transport between complex I–II and II–III of the electron 
transport chain, one possibility is that the reduced respira-
tory capacity observed in 24-month-old hearts is associated 
with CoQ deficiency.21 Previous reports have demonstrated 
an age-related decline in mitochondrial respiration; however, 
the extent of this decline varies between reports and shows 
discrepancies between rodent strains.22-24 In addition, previous 
studies vary with respect to whether particular mitochondrial 
subsarcomel subpopulation, interfibrillar subpopulation or 
total isolated mitochondria are analyzed.23-25 The mitochon-
drial function studies within the present study consist of all 
mitochondrial populations within the cardiac tissue but do 
not take into account factors such as mitochondrial density 
or cell numbers.
One caveat of this study is that mitochondrial respiratory 
capacity was examined in native heart tissue but not in heart 
tissue subjected to DCD with or without pharmacologic con-
ditioning supplements. However, we have previously found the 
addition of GTN or cariporide (another NHE inhibitor), either 
FIGURE 2. Baseline characteristics of aged rats and hemodynamics at the end of 30 min working mode reperfusion in the absence of warm 
ischemia. A, Rat body weight, n=11–12; (B) heart wet weight, 12-mo and 18-mo n = 3, 24-mo n = 8; (C) baseline aortic flow, 12-mo and 18-mo 
n = 6, 24-mo n = 2; (D) baseline coronary flow, 12-mo and 18-mo n=6, 24-mo n = 2; (E) baseline coronary flow normalized to heart wet weight, 
12-mo and 18-mo n = 6, 24-mo n = 2; (F) baseline cardiac output, 12-mo and 18-mo n = 6, 24-mo n = 2. Bars represent mean ± SEM; 1-way 
analysis of variance with Tukey multiple comparisons test. ***P ≤ 0.0002 vs 12-mo group.
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FIGURE 3. Cardiac functional recovery of unsupplemented (C, solid bars) and supplemented (CS, open bars) aged donation after circulatory 
death hearts at the end of working mode reperfusion. (A) Aortic flow recovery; (B) coronary flow recovery; (C) cardiac output recovery. Bars 
represent mean ± SEM; 2-way analysis of variance with Sidak multiple comparisons test comparing unsupplemented vs supplemented groups 
within each age group. *P = 0.0198; all groups n = 6 except 24-mo unsupplemented n = 5. C, Celsior only group; CS, Celsior supplemented 
with GTN/EPO/zoniporide; EPO, erythropoietin; GTN, glyceryl trinitrate.
FIGURE 4. LDH efflux of unsupplemented (solid bars) or supplemented (open bars) hearts during working mode reperfusion after (A), 1 min; 
(B), 15 min; and (C), 30 min. Bars represent mean ± SEM; n = 4–6 per group. LDH, lactate dehydrogenase.
FIGURE 5. Mitochondrial respiratory capacity from 3-mo (open bars), 12-mo (gray bars) and 24-mo (black bars) old rat hearts. Bars represent 
mean ± SEM. Two-way analysis of variance with Tukey multiple comparisons test; 3-mo n = 4, 12-mo n = 6, 24-mo n = 5. ****P < 0.0001; ***P 
< 0.001; **P < 0.01; and *P < 0.03. ETS, electron transport system capacity; LN, leak respiration in the absence of adenylates; PCI, submaximal 
state 3 respiratory capacity specific to complex I; PCII, submaximal state 3 respiratory capacity specific to complex III; PETF, maximal electron flow 
via electron-transferring flavoprotein; PMAX, maximal state 3 respiration; ROX, residual oxygen consumption; V, volume.
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singly or together during arrest and storage of donor rat hearts 
resulted in cardioprotective signaling favoring mitophagy acti-
vation (ERK and Bcl2 phosphorylation) and maintenance of 
mitochondrial transition pore closure post-reperfusion (STAT3 
and ERK phosphorylation) which were crucial for functional 
recovery of the donor heart.26 In addition, previously unrec-
ognized GTN reductase activity of mitochondrial aldehyde 
dehydrogenase has been demonstrated to be responsible for 
bioactivation of GTN, by reduction to NO and further con-
version to S-nitrosothiols,27 potentially contributing to mito-
chondrial protection. Nitrosylation of a key Cys residue on 
complex I of the electron transport chain can transiently pre-
vent oxidant formation via reverse electron transport through 
complex I as a result of succinate accumulation during warm 
ischemia,28-30 such as after WLS. The loss of ischemic tolerance 
may be related to mitochondrial dysfunction and we have 
shown a decline in age-related mitochondrial capacity. The 
limited effects of pharmacologic supplementation in hearts 
from older donors may be due to an increased susceptibility 
of mitochondrial permeability transition pore (mPTP) open-
ing since aged cardiomyocytes exhibit reduced time to mPTP 
opening in response to an apoptotic stimulus22 and are more 
susceptible to mPTP opening after calcium overload.31 Current 
clinical supplementations aim to inhibit mPTP opening; how-
ever, perhaps the efficacy of supplementation is reduced in 
older hearts. It is also possible that the increased susceptibil-
ity to ischemia in older donors, and lack of responsiveness to 
pharmacologic supplementation, may be due to downregula-
tion of current known protective pathways.32,33
There are some limitations of this study to consider. The 
current study investigates the effects of ischemia on donor's 
hearts in an ex-situ setting but does not take into account 
the posttransplant milieu of the recipient. This study has also 
solely used hearts from aged male rodents and the effects of 
supplementation on aged female rodent hearts have not been 
examined. However, our clinical translation of our DCD pro-
tocol suggests that there would be minimal sex differences. 
Indeed, as yet we have not observed severe primary graft 
dysfunction in any recipient of a heart from a female DCD 
donor.6 Another major limitation is the feasibility of aging 
rodent studies due to the high financial costs of animal main-
tenance to account for attrition rates. In the current study, we 
were unable to assess mitochondrial function in the 18-month 
cohort due to a lack of additional animals at this particular 
time point. The clear differences in mitochondrial function 
between 12 months and 24 months animals indicate an age-
related decline in mitochondrial function; however, whether a 
reduction in mitochondrial respiratory capacity is evident in 
18-month animals compared to 12 months is still unknown.
The implications from our current data are 2-fold. First, as 
aging is common to both the donor and recipient populations, 
the effect of dwindling ischemic tolerance in older donors may 
impact on the recovery of the donor’s heart. Indeed, a large 
UNOS registry examining the interaction between donor 
age and ischemic time in human heart transplant recipients 
showed that ischemic tolerance declined as the age group 
increased across 3 age terciles: <20 years, 20–33 years, and 
>34 years.34 Although in the present study, senescent mark-
ers were not shown, the age groups from the UNOS regis-
try34 would not be considered as senescent, yet the impact of 
increasing age on tolerance to ischemia-reperfusion injury 
is clear. Indeed, the average age of the oldest tercile in the 
study by Russo et al34 was 44 years old, which corresponds 
closely to the 18-month-old rats in the present study which 
also displayed a reduced ischemic tolerance. Second, the data 
from this study raise the question of whether the current age 
limit for clinical DCD heart utilization (55 y in our clinical 
DCD heart transplant program6) is appropriate given that the 
benefits of currently available pharmacologic supplements are 
negated in older donors within the present study.
Although upregulation of protective mechanisms using 
pharmacologic strategies is effective, the current rodent model 
suggests that in the elderly, there is irreversible attenuation of 
these pathways rendering these hearts at risk to irreparable 
ischemic injury. In conclusion, this study shows an age-related 
decline to ischemia-reperfusion injury in rodent DCD hearts 
and suggests continued caution in the clinical use of older 
DCD hearts for transplantation; however, further understand-
ing of the human DCD heart is required before extending the 
donor age limit.
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